Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 5/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14293610 | 0.94 | KDM4E (0.69) | KDM4EALOX15NOS1MPOKMT2A | |
| SCHEMBL4413889 | 0.89 | KDM4E (0.56) | KDM4EALOX15MPOKMT2ACHRM2 | |
| SCHEMBL4404501 | 0.87 | KDM4E (0.55) | KDM4EALOX15NOS1KMT2ANOS3 | |
| SCHEMBL4404341 | 0.85 | KDM4E (0.50) | KDM4EALOX15KMT2ACHRM2ALDH1A1 | |
| SCHEMBL4413514 | 0.85 | KDM4E (0.50) | KDM4EALOX15KMT2ACHRM2ALDH1A1 | |
| SCHEMBL4404505 | 0.84 | CHRM2 (0.53) | KDM4EALOX15KMT2ACHRM2ALDH1A1 | |
| SCHEMBL4409049 | 0.84 | KDM4E (0.51) | KDM4EALOX15KMT2ACHRM2ALDH1A1 | |
| SCHEMBL14293672 | 0.83 | KDM4E (0.52) | KDM4EALOX15MPOKMT2ACHRM2 | |
| SCHEMBL14293606 | 0.82 | KDM4E (0.52) | KDM4EALOX15NOS1KMT2ANOS3 | |
| SCHEMBL4409089 | 0.82 | CHRM2 (0.57) | KDM4EALOX15KMT2ACHRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608352-B1 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2009-12-30 | — | — | EP | disclosed |
| US-7504422-B2 | Polyamine compounds | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2009-03-17 | — | — | US | disclosed |
| US-7504422-B2 | Polyamine compounds | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2009-03-17 | — | — | US | disclosed |
| US-7504422-B2 | Polyamine compounds | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2009-03-17 | — | — | US | disclosed |
| US-7399776-B2 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-7399776-B2 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-7399776-B2 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
| WO-2008021788-A2 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (CN) | 2008-02-21 | — | — | WO | disclosed |
| EP-1608352-A4 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2007-11-28 | — | — | EP | disclosed |
| EP-1608352-A1 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | Taigen Biotechnology (TW) | 2005-12-28 | — | — | EP | disclosed |
| US-20050043366-A1 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2005-02-24 | — | — | US | disclosed |
| WO-2004089360-A1 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | TAIGEN BIOTECHNOLOGY (TW) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043366-A1 | Polyamine compounds for treating chemokine receptor mediated diseases | CCL2, CCR2, CCR5 | KDM4E 3882/4885ALOX15 1087/4885NOS1 503/4885 |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | SRM, SMS, SMOX | KDM4E 1061/4885ALOX15 1349/4885NOS1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.